Preventing type 1 diabetes development and preserving beta-cell function

• Published in: Current opinion in endocrinology, diabetes, and obesity Vol. 29; no. 4; pp. 386 - 391
• Main Authors: Mastrandrea, Lucy D., Quattrin, Teresa
• Format: Journal Article
• Language: English
• Published: England Lippincott Williams & Wilkins 01-08-2022
• Subjects: Autoimmunity; Diabetes Mellitus, Type 1; Humans; Insulin - therapeutic use; Insulin-Secreting Cells; Quality of Life
• ISSN: 1752-296X; 1752-2978
• DOI: 10.1097/MED.0000000000000746

Type 1 diabetes (T1D) is the most common chronic disease of childhood presenting a significant burden, both in terms of day-to-day medical management and lifelong care. Studies aligned with diverse strategies to prevent or modify the course of T1D are reviewed.
The diagnosis of T1D precedes the classic clinical presentation when insulin dependence develops. With an increased understanding of the pathophysiology of the autoimmune process leading to T1D, treatment strategies to prevent the development of autoimmunity and/or modify the immune response have been trialed in persons at risk for developing the disease. Interventions prior to insulin dependence or very early after clinical diagnosis show some promise both in preventing disease onset and prolonging beta-cell insulin production.
Significant progress has been made in the treatment of T1D. However, suboptimal glycemic control remains a challenge impacting overall health and quality of life for patients with this chronic disease. Although physicians and basic sciences investigators continue to pursue the prevention of the autoimmune process, the advent of disease-modifying agents is a promising strategy. Further studies are needed to ensure that insulin preservation can be achieved longer term.